For other characteristics relevant to clinical outcomes of CRC, they did not show significant difference between patients with NTRK3 promoter hypermethylation and hypomethylation, including age, sex, tumor size, tumor differentiation, lymphovascular invasion, perineural invasion, TNM stage, CIMP, BRAF mutation, Ki-67, CA19-9, and CEA. Here, NTRK3 is linked to colorectal carcinoma.